Lawrence Klein, a director and officer of Oruka Therapeutics, Inc., filed a Form 144 notice on November 2, 2026, proposing the sale of 25,000 shares of common stock on NASDAQ following the exercise of stock options.
Key Highlights
- Proposed sale: Lawrence Klein intends to sell 25,000 shares of Oruka Therapeutics common stock, with an aggregate market value of $2,421,750.00, according to the filing.
- Acquisition method: The 25,000 shares were acquired on November 2, 2026, through the exercise of stock options from the issuer, with cash payment on the same date.
- Trading plan: The filing indicates reliance on a Rule 10b5-1 plan adopted on May 14, 2026.
- Shares outstanding: The filing reports 66,209,699 shares of common stock outstanding at the time of notice.
- Prior sales in past 3 months: Klein sold 25,000 shares on October 1, 2026 (gross proceeds $2,090,592.50), 2,452 shares on September 15, 2026 (gross proceeds $234,680.92), and 75,000 shares on September 1, 2026 (gross proceeds $6,887,490.00), all reported as 10b5-1 sales except the September 15 sale.
- Broker: The proposed sale is to be conducted through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.
Klein's Proposed Stock Sale Details and Recent Transaction History at Oruka Therapeutics
According to the Form 144 filed with the U.S. Securities and Exchange Commission, Lawrence Klein, who holds the roles of both director and officer at Oruka Therapeutics, Inc. (NASDAQ:ORKA), filed a notice of proposed sale on November 2, 2026. The filing covers the proposed sale of 25,000 shares of the company's common stock, with an aggregate market value listed as $2,421,750.00. The approximate date of sale is noted as November 2, 2026.
The filing discloses that the 25,000 shares subject to this notice were acquired on November 2, 2026, through the exercise of stock options granted by the issuer, with the consideration described as cash paid on the same date. The notice states that Klein is relying on a Rule 10b5-1 written trading plan, with an adoption date of May 14, 2026. Oruka Therapeutics is headquartered at 855 Oak Grove Avenue, Suite 100, Menlo Park, California 94025.
The filing also discloses sales of Oruka Therapeutics common stock by Klein during the preceding three months. These include a 10b5-1 sale of 75,000 shares on September 1, 2026, with gross proceeds of $6,887,490.00; a sale of 2,452 shares on September 15, 2026, with gross proceeds of $234,680.92; and a 10b5-1 sale of 25,000 shares on October 1, 2026, with gross proceeds of $2,090,592.50. The filing was signed by Lawrence Klein, who represented, as required by the form, that he does not know any material adverse information regarding the issuer's current and prospective operations that has not been publicly disclosed.
What Was Disclosed
Lawrence Klein filed a Form 144 notice proposing the sale of 25,000 Oruka Therapeutics common shares acquired via stock option exercise, under a 10b5-1 plan adopted May 14, 2026, with an aggregate market value of $2,421,750.00 and an approximate sale date of November 2, 2026.



Please wait processing your request...